[ad_1]
The recent registration of one of the most promising vaccines for protection against coronavirus, that of the pharmaceutical company AstraZeneca, developed in collaboration with scientists at the University of Oxford, has been called into question.
You will probably need additional clinical trials. This could seriously delay the next mass immunization in Britain and the EU, he said. Deutsche Welle.
What is specific about this development is that it will be cheap (probably five dollars for two doses) and can be stored and transported in common refrigerators. This is why it is very different from the vaccine from BioNTech and Pfizer, which requires a temperature of minus 70 degrees, which seriously complicates logistics.
However, there are also doubts about the development of AstraZeneca. Why was a group of volunteers, including 2,700 people, vaccinated first with half the dose and a month later with the full dose, when the larger group of about 8,900 people received two full doses? And why in the first case the efficiency turns out to be at a very high level of 90% and in the second it is only 62%?
“We used half a dose by chance,” Rene Pangalos, who is in charge of development at AstraZeneca, told Reuters. It was a very common mistake: people received a different dose than planned. And it is the fault of the manufacturer who delivered such doses.
Dose omissions were made in the course of clinical trials of the Oxford vaccine, immediately prompting strong criticism at the expert level, not about the vaccine itself, but about AstraZeneca’s reporting methodology and its reporting policy. information.
In addition, experts point out that in this group, none of those immunized was over 55 years old, that is. the scheme has not been tested in the elderly.
As a result of criticism from experts, on November 26, AstraZeneca CEO Pascal Sorio announced that more research would be conducted on the vaccine, designed to complement the results thus far. The scale and duration of these studies are not yet known, but in any case they will delay the registration of the Oxford vaccine and its launch on the world market.
Photo :: BGNES
I like our Facebook page HERE
